Cargando…
The immuno-oncology framework: Enabling a new era of cancer therapy
Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient’s immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This...
Autores principales: | Hoos, Axel, Britten, Cedrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382871/ https://www.ncbi.nlm.nih.gov/pubmed/22737609 http://dx.doi.org/10.4161/onci.19268 |
Ejemplares similares
-
Greater patient access to immuno-oncology therapies—what can policymakers do?
por: de Lorenzo, Francesco, et al.
Publicado: (2015) -
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
por: Hoos, Axel, et al.
Publicado: (2012) -
Organoids as an Enabler of Precision Immuno-Oncology
por: Zhao, Junzhe, et al.
Publicado: (2023) -
Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017) -
The hubris and humility of cancer pharmacology in the post immuno‐oncology era
por: Lazo, John S.
Publicado: (2019)